Legal & General Group Plc boosted its stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) by 5,474.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,773,799 shares of the company’s stock after acquiring an additional 1,741,978 shares during the period. Legal & General Group Plc owned 1.85% of Bio-Path Holdings worth $681,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in BPTH. Tower Research Capital LLC TRC bought a new stake in Bio-Path Holdings in the first quarter worth about $105,000. Bank of New York Mellon Corp raised its position in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares during the period. Sabby Management LLC raised its position in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after acquiring an additional 23,352 shares during the period. Finally, HighTower Advisors LLC raised its position in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after acquiring an additional 105,000 shares during the period. 15.16% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bio-Path Holdings, Inc. (BPTH) opened at 0.3728 on Thursday. Bio-Path Holdings, Inc. has a 52-week low of $0.25 and a 52-week high of $1.50. The company’s market cap is $37.30 million. The stock has a 50 day moving average of $0.33 and a 200 day moving average of $0.46.

Bio-Path Holdings (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). On average, equities research analysts expect that Bio-Path Holdings, Inc. will post ($0.08) EPS for the current year.

BPTH has been the topic of several research reports. HC Wainwright reissued a “buy” rating on shares of Bio-Path Holdings in a research report on Thursday, July 20th. Zacks Investment Research lowered shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine lowered shares of Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

ILLEGAL ACTIVITY NOTICE: “Legal & General Group Plc Increases Holdings in Bio-Path Holdings, Inc. (BPTH)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/05/legal-general-group-plc-increases-holdings-in-bio-path-holdings-inc-bpth.html.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Want to see what other hedge funds are holding BPTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Path Holdings, Inc. (NASDAQ:BPTH).

Institutional Ownership by Quarter for Bio-Path Holdings (NASDAQ:BPTH)

Receive News & Stock Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related stocks with our FREE daily email newsletter.